Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 04, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's own ordinary shares, executed under authority granted at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital movements.
- Shares Purchased: 1,250,000 ordinary shares.
- Purchase Price: 1,110.66 pence per share.
- Purchase Date: June 03, 2008.
- Treasury Shares Held: 484,194,158 shares (representing 9.08% of total voting rights).
- Shares in Issue: 5,334,886,409 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 1,250,000 repurchased shares. Consequently, the number of shares held in Treasury increased to 484,194,158. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It includes a standard disclaimer stating that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (5,334,886,409) for calculating ownership percentages under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (484,194,158) and its impact on the total voting rights structure (9.08% held in Treasury).
- Review the Annual General Meeting minutes from May 21, 2008, to understand the full scope of the share buyback authority utilized.